Trial · NCT07895628
A Crossover Study Evaluating the Postprandial Glycemic Response of Three Sweeteners in a Mixed Meal Setting
NCT07895628, Not applicable, Recruiting, LOAM Science
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Crossover Study Evaluating the Postprandial Glycemic Response of Three Sweeteners in a Mixed Meal Setting. Trials, record NCT07895628. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07895628
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Crossover Study Evaluating the Postprandial Glycemic Response of Three Sweeteners in a Mixed Meal Setting
- NCT number
- NCT07895628
- Status
- Recruiting
- Phases
- Not applicable
- Enrollment
- 50 participants, estimated
- Lead sponsor
- LOAM Science
- Conditions
- Postprandial Glucose, GI Tolerance
- Interventions
- LOAM Fiber-based Sweetener, Sugar, Stevia
- First posted
- 2026-10-26
- Last updated
- 2026-11-12
Source ClinicalTrials.gov
Registered outcomes7
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Postprandial Area Under the Curve to 120 Minutes | Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10. | Area under the curve above baseline from time zero (the start of the preload consumption) through 120 minutes. Baseline is defined as the mean glucose over the 15 minutes prior to the preload consumption. Area falling below baseline will be excluded. |
| Secondary | Postprandial Area Under the Curve to 180 Minutes | Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10. | Area under the curve above baseline from time zero (the start of the preload consumption) through 180 minutes. Baseline is defined as the mean glucose over the 15 minutes prior to the preload consumption. Area falling below baseline will be excluded. |
| Secondary | Postprandial Area Under the Curve to 120 Minutes Relative to Start of the Meal | Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10. | Area under the curve above baseline from time zero (the start of the meal consumption) through 120 minutes. Baseline is defined as the mean glucose over the 15 minutes prior to the preload consumption. Area falling below baseline will be excluded. |
| Secondary | Peak Glucose | Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10. | Maximum observed glucose peak over the course of the 180 minute window. |
| Secondary | Incremental Peak Glucose | Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10. | Maximum observed glucose peak relative to baseline over the course of the 180 minute window. |
| Secondary | Time to Peak | Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10. | Elapsed time from preload consumption to the maximum observed value. |
| Secondary | Post-Meal Subjective State | Data will be collected on each day of supplementation, days 3, 4, 6, 7, 9, and 10. | Fullness, hunger, energy, and gastrointestinal comfort on a 0-10 numerical rating scale with 10 being an optimal situation and 0 representing the inverse for fullness, energy, and gastrointestinal comfort and 0 being an optimal situation and 10 representing the inverse for hunger. Questions are asked 60 and 180 minutes after the start of the mixed meal. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07895628
GET https://conductscience.org/api/trials/v1/NCT07895628/registered